News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

NPS Pharmaceuticals, Inc. (NPSP) Reports Characteristics of Patients Who Achieved Independence from Parenteral Support in STEPS 2 Study of Gattex® (teduglutide) in Adult Short Bowel Syndrome


10/22/2012 9:34:27 AM

BEDMINSTER, N.J.--(BUSINESS WIRE)--NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a biopharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today reported data related to the seven patients who achieved complete independence from parenteral nutrition (PN) and/or intravenous fluids (IV) while on long-term Gattex® (teduglutide) therapy in STEPS 2, a 24-month, open-label study in adult short bowel syndrome (SBS).

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES